Skip to main content Accessibility help

Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation

  • Guy A. Cabral (a1) and LaToya Griffin-Thomas (a1)


There is now a large body of data indicating that the cannabinoid receptor type 2 (CB2) is linked to a variety of immune events. This functional relevance appears to be most salient in the course of inflammation, a process during which there is an increased number of receptors that are available for activation. Studies aimed at elucidating signal transduction events resulting from CB2 interaction with its native ligands, and of the role of exogenous cannabinoids in modulating this process, are providing novel insights into the role of CB2 in maintaining a homeostatic immune balance within the host. Furthermore, these studies suggest that the CB2 may serve as a selective molecular target for therapeutic manipulation of untoward immune responses, including those associated with a variety of neuropathies that exhibit a hyperinflammatory component.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
      Available formats


Corresponding author

*Corresponding author: Guy A. Cabral, Department of Microbiology and Immunology, Virginia Commonwealth University, School of Medicine, 1101 E. Marshall Street, Richmond, VA 23298-0678, USA. Tel: +1 804 828 2306; Fax: +1 804 828 8220; E-mail:


Hide All
1Gauthier, K.M. et al. (2005) Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. American Journal of Physiology – Heart and Circulatory Physiology 288, H1344-H1351
2Gonthier, M-P. et al. (2007) Identification of endocannabinoids and related compounds in human fat cells. Obesity 15, 837-845
3Walter, L. et al. (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. Journal of Neuroscience 23, 1398-1405
4Di Marzo, V. et al. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. European Journal of Biochemistry 264, 258-267
5Maejima, T. et al. (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475
6Devane, W.A. et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949
7Mechoulam, R. et al. (1995) Identification of an endogenous 2-monoglyceride present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50, 83-90
8Dinh, T.P. et al. (2002a) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of the United States of America 99, 10819-10824
9Dinh, T.P. et al. (2002b) A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chemistry and Physics of Lipids 121, 149-158
10Saario, S.M. et al. (2004) Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochemical Pharmacology, 67, 1381-1387
11Di Marzo, V. et al. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691
12Beltramo, M. et al. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097
13Rakhshan, F. et al. (2000) Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells. Journal of Pharmacology and Experimental Therapeutics 292, 960-967
14Day, T.A. et al. (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Molecular Pharmacology 59, 1369-1375
15Gardner, B. et al. (2003) Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB Journal 17, 2157-2159
16Hinz, B. et al. (2004) R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochemical and Biophysical Research Communications 324, 621-626
17Oz, M. (2006) Receptor-independent actions of cannabinoids on cell membranes: Focus on endocannabinoids. Pharmacology and Therapeutics 111, 114-144
18De Morrow, S. et al. (2007) Opposing actions of endocannabinoids on cholangiocarcinoma growth. Recruitment of Fas and Fas ligand to lipid rafts. Journal of Biological Chemistry 282, 13098-13113
19Howlett, A.C. and Fleming, R.M. (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology 26, 532-538
20Howlett, A.C. (1985) Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Molecular Pharmacology 27, 429-436
21Howlett, A.C., Qualy, J.M. and Khachatrian, L.L. (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology 29, 307-313
22Matsuda, L.A. et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564
23Herkenham, M. et al. (1990) Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 87, 1932-1936
24Westlake, T.M. et al. (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63, 637-652
25Howlett, A.C. and Mukhopadhyay, S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chemistry and Physics of Lipids 108, 53-70
26Demuth, D.G. and Molleman, A. (2006) Cannabinoid signalling. Life Sciences 78, 546-563
27Gifford, A.N. et al. (2002) In vivo imaging of the brain cannabinoid receptor. Chemistry and Physics of Lipids 121, 65-72
28Munro, S., Thomas, K.L. and Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65
29Griffin, G. et al. (2000) Cloning and pharmacological characterization of the rat CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics 292, 888-894
30Brown, S.M. et al. (2002) Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica et Biophysica Acta 1576, 255-264
31Bouaboula, M. et al. (1999) Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR144528. Implications for receptor biological responses. Journal of Biological Chemistry 274, 20397-20405
32Galiegue, S. et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232, 54-61
33Schatz, A.R. et al. (1997) Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicology and Applied Pharmacology 142, 278-287
34Nunez, E. et al. (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse 53, 208-213
35Ramirez, B.G. et al. (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. Journal of Neuroscience 25, 1904-1913
36Cabral, G.A. and Marciano-Cabral, F. (2005) Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. Journal of Leukocyte Biology 78, 1192-1197
37Fernandez-Ruiz, J. et al. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends in Pharmacological Sciences 28, 39-45
38Sawzdargo, M. et al. (1999) Identification and cloning of three novel human G protein-coupledreceptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Molecular Brain Research 64, 193-198
39Baker, D. et al. (2006) In silico patent searching reveals a new cannabinoid receptor. Trends in Pharmacological Sciences 27, 1-4
40Pertwee, R.G. (2007) GPR55: a new member of the cannabinoid receptor clan? British Journal of Pharmacology 152, 984-986
41Ryberg, E. et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 152, 1092-1101
42Lauckner, J.E. et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proceedings of the National Academy of Sciences of the United States of America 105, 2699-2704
43Caterina, M.J. et al. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824
44Szallasi, A. (2002) Vanilloid (capsaicin) receptors in health and disease. American Journal of Clinical Pathology 118, 110-121
45Melck, D. et al. (1999) Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochemical and Biophysical Research Communications 262, 275-284
46Zygmunt, P.M. et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457
47Smart, D. et al. (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). British Journal of Pharmacology 129, 227-230
48Ross, R.A. (2003) Anandamide and vanilloid TRVP1 receptors. British Journal of Pharmacology 140, 790-801
49Jarai, Z. et al. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America 96, 14136-14141
50Di Marzo, V. et al. (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry 75, 2434-2444
51Breivogel, C.S. et al. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 60, 155-163
52Wiley, J.L. and Martin, B.D. (2002) Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chemistry and Physics of Lipids 121, 57-63
53Bayewitch, M. et al. (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Letters 375, 143-147
54Slipetz, D.M. et al. (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Molecular Pharmacology 48, 352-361
55Bouaboula, M. et al. (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. European Journal of Biochemistry 237, 704-711
56Zoratti, C. et al. (2003) Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. British Journal of Pharmacology 140, 1351-1362
57Cabral, G.A. et al. (2008) CB2 receptors in the brain: role in central immune function. British Journal of Pharmacology 153, 240-251
58Cabral, G.A. and Staab, A. (2005) Effects on the immune system. Handbook of Experimental Pharmacology 168, 385-423
59Morahan, P.S. et al. (1979) Effects of cannabinoids on host resistance to Listeria monocytogenes and herpes simplex virus. Infection and Immunity 23, 670-674
60Juel-Jensen, B.E. (1972) Cannabis and recurrent herpes simplex. British Medical Journal. 4, 296
61Cabral, G.A. and Dove-Pettit, D.A. (1998) Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. Journal of Neuroimmunology 83, 116-123
62Klein, T.W., Newton, C. and Friedman, H. (1998) Cannabinoid receptors and immunity. Immunology Today 19, 373-381
63Arata, S. et al. (1992) Enhanced growth of Legionella pneumophila in tetrahydrocannabinol-treated macrophages. Proceedings of the Society for Experimental Biology and Medicine 199, 65-67
64Arata, S. et al. (1991) Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures. Life Sciences 49, 473-479
65Marciano-Cabral, F. et al. (2001) Delta-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, exacerbates brain infection by Acanthamoeba. Journal of Eukaryotic Microbiology (Suppl), 4S-5S
66Newton, C.A., Klein, T. and Friedman, H. (1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infection and Immunity 62, 4015-4020
67Burnette-Curley, D. and Cabral, G.A. (1995) Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9tetrahydrocannabinol. Proceedings of the Society for Experimental Biology and Medicine 210, 64-76
68Coffey, R.G. et al. (1996) Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochemical Pharmacology 52, 743-751
69Klein, T.W. et al. (1991) Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. Journal of Toxicology and Environmental Health 32, 465-477
70McCoy, K.L. et al. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. Journal of Pharmacology and Experimental Therapeutics 289, 1620-1625
71Raborn, E.S. et al. (2008) The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB(2) receptor. Journal of Neuroimmune Pharmacology 3, 117-129
72Sacerdote, P. et al. (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decrease the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. Journal of Neuroimmunology 109, 155-163
73Ullrich, O. et al. (2007) Immune control by endocannabinoids - new mechanisms of neuroprotection? Journal of Neuroimmunology 184, 127-135
74Cabral, G.A. and Marciano-Cabral, F. (2004) Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. Journal of Neuroimmunology 147, 127-130
75Steffens, S. et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786
76Kishimoto, S. et al. (2003) 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. Journal of Biological Chemistry 278, 24469-24475
77Derocq, J. et al. (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Letters 369, 177-182
78Carayon, P. et al. (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92, 3605-3615
79Friedman, H. et al. (1991) Immunosuppression by marijuana components. In Psychoneuroimmunology ( Ader, R., Felten, D.L. and Cohen, N., eds.), pp. 931-953, Academic Press
80Klein, T. et al. (1998b) Marijuana, immunity and infection. Journal of Neuroimmunology 83, 102-115
81Kaminski, N. et al. (1994) Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochemical Pharmacology 48, 1899-1908
82Massi, P. et al. (2000) Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. European Journal of Pharmacology 387, 343-347
83Klein, T.W. et al. (2000) Delta-9- tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. Journal of Immunology 164, 6461-6466
84Zhu, L.X. et al. (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. Journal of Immunology 165, 373-380
85Berdyshev, E.V. et al. (1997) Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. European Journal of Pharmacology 330, 231-240
86Facci, L. et al. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences of the United States of America 92, 3376-3380
87Joseph, J. et al. (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunology, Immunotherapy 53, 723-728
88Valk, P. et al. (1997) Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90, 1448-1457
89Molina-Holgado, F. et al. (1998) The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Letters 433, 139-142
90Stefano, G.B. et al. (2000) 2-Arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacological Research 42, 317-322
91Jorda, M.A. et al. (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99, 2786-2793
92Rayman, N. et al. (2004) Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. Journal of Immunology 172, 2111-2117
93Kishimoto, S. et al. (2004) 2-Arachidonoylglycerol an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. Journal of Biochemistry (Tokyo) 135, 517-524
94Carrier, E.J. et al. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Molecular Pharmacology 65, 999-1007
95Klein, T.W. and Friedman, H. (1990) Modulation of murine immune cell function by marijuana components. In Drugs of Abuse and Immune Function ( Watson, R., ed.), pp. 87-111, CRC Press
96Burnette-Curley, D. et al. (1993) Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. International Journal of Immunopharmacology 15, 371-382
97Cabral, G.A. and Mishkin, E.M. (1989) Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators. Journal of Toxicology and Environmental Health 26, 175-182
98Watzl, B. et al. (1991) Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. In Advances in Experimental Medicine and Biology ( Friedman, H., Specter, S. and Klein, T.W., eds), pp. 63-70, Plenum Press
99Nakano, Y. et al. (1992) Modulation of interleukin 2 activity by delta 9-tetrahydrocannabinol after stimulation with concanavalin A, phytohemagglutinin, or anti-CD3 antibody. Proceedings of the Society for Experimental Biology and Medicine 201, 165-168
100Puffenbarger, R.A. et al. (2000) Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69
101Jeon, Y.J. et al. (1996) Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Molecular Pharmacology 50, 334-341
102Adams, D.O. and Hamilton, T.A. (1984) The cell biology of macrophage activation. Annual Review of Immunology 2, 283-318
103Hamilton, T.A. and Adams, D.O. (1987) Molecular mechanisms of signal transduction in macrophages. Immunology Today 8, 151-158
104Hamilton, T.A. et al. (1986) Effects of bacterial lipopolysaccharide on protein synthesis in murine peritoneal macrophages: Relationship to activation for macrophage tumoricidal function. Journal of Cellular Physiology 128, 9-17
105Carlisle, S. et al. (2002) Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. International Immunopharmacology 2, 69-82
106Harris, H. (1953) Chemotaxis of monocytes. British Journal of Experimental Pathology 34, 276-279
107Harris, H. (1954) Role of chemotaxis in inflammation. Physiological Reviews 34, 529-562
108Jin, T. and Hereld, D. (2006) Moving toward understanding eukaryotic chemotaxis. European Journal of Cell Biology 85, 905-913
109Kehrl, J.H. (2006) Chemoattractant receptor signaling and the control of lymphocyte migration. Immunologic Research 34, 211-227
110Becker, E.L. (1977) Stimulated neutrophil locomotion: chemokinesis and chemotaxis. Archives of Pathology and Laboratory Medicine 101, 509-513
111Keller, H.U. et al. (1978) Distinct chemokinetic and chemotactic responses in neutrophil granulocytes. European Journal of Immunology 8, 1-7
112Lauffenburger, D.A. and Horwitz, A.F. (1996) Cell migration: a physically integrated molecular process. Cell 84, 359-369
113Mitchison, T.J. and Cramer, L.P. (1996) Actin-based cell motility and cell locomotion. Cell 84, 371-379
114Murdoch, C. and Finn, A. (2000) Chemokine receptors and their role in inflammation and infectious disease. Blood 95, 3032-3043
115Schiffmann, E. et al. (1975) N-formyl-methionyl peptides as chemoattractants for leucocytes. Proceedings of the National Academy of Sciences of the United States of America 72, 1059-1062
116Goldman, D.W. and Goetzl, E.J. (1982) Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes. Journal of Immunology 129, 1600-1604
117Hanahan, D.J. (1986) Platelet activating factor: A biologically active phosphoglyceride. Annual Review of Biochemistry 55, 483-509
118Gerard, C. and Gerard, N.P. (1994) C5A anaphylatoxin and its seven transmembrane-segment receptor. Annual Review of Immunology 12, 775-808
119Baggiolini, M. et al. (1994) Interleukin-8 and related chemotactic cytokines CXC and CC chemokines. Advances in Immunology 55, 97-179
120Baggiolini, M. et al. (1997) Human chemokines: an update. Annual Review of Immunology 15, 675-705
121Kim, C.H. (2004) Chemokine-chemokine receptor network in immune cell trafficking. Current Drug Targets – Immune, Endocrine & Metabolic Disorders 4, 343-361
122Le, Y. et al. (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Molecular Immunology 1, 95-104
123Charo, I.F. and Ransohoff, R.M. (2006) Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine 354, 610-621
124Sacerdote, P. et al. (2005) The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. Journal of Neuroimmunology 159, 97-105
125Buckley, N.E. et al. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. European Journal of Pharmacology 396, 141-149
126Buckley, N.E. (2008) The peripheral cannabinoid receptor knockout mice: an update. European Journal of Pharmacology 153, 309-318
127Van Sickle, M.D. et al. (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332
128Gong, J-P. et al. (2006) Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Research 1071, 10-23
129Onaivi, E.S. (2006) Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54, 231-246
130Onaivi, E.S. et al. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in the brain. Annals of the New York Academy of Sciences 1074, 514-536
131Grimsey, N.L. et al. (2008) Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! Journal of Neuroscience Methods 171, 78-86
132Shohami, E. et al. (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Journal of Neuroimmunology 72, 169-177
133Cabral, G.A. et al. (2001) Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Advances in Experimental Medicine and Biology 493, 207-214
134Molina-Holgado, F. et al. (2002) Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. Journal of Neuroscience Research 67, 829-836
135Klegeris, A. et al. (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology 139, 775-786
136Sheng, W.S. et al. (2005) Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219
137Kreutzberg, G.W. (1996) Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences 19, 312-318
138Benveniste, E.N. (1997) Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. Journal of Molecular Medicine 75, 165-173
139 Giulian, D. and Baker, T.J. (1986) Characterization of ameboid microglia isolated from developing mammalian brain. Journal of Neuroscience 6, 2163-2178
140Dickson, D.W. (1997) Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiology of Aging 18, S21-S26
141Selkoe, D.J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends in Cell Biology 8, 447-453
142Velez-Pardo, C. and Del Rio, M.J. (2006) Avoidance of Abeta[(25–35)]/(H2O2)-induced apoptosis in lymphocytes by the cannabinoid agonists CP55,940 and JWJ-015 via receptor-independent and PI3K-dependedent mechanisms: role of NF-kappaB and p53. Medicinal Chemistry 2, 471-479
143Raine, C.S. and Wu, E. (1993) Multiple sclerosis: remyelination in acute lesions. Journal of Neuropathology and Experimental Neurology 52, 199-204
144Racke, M.K. (2001) Experimental autoimmune encephalomyelitis (EAE). Current Protocols in Neuroscience 9, Unit 9.7
145Calderon, T.M. et al. (2006) A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. Journal of Neuroimmunology 177, 27-39
146Kieseier, B.C. et al. (1999) Matrix metalloproteinases exhibit different expression patterns in inflammatory demyelinating diseases of the central and peripheral nervous system. Annals of the New York Academy of Sciences 878, 567-570
147Anthony, D.C. et al. (2000) The evidence for primary axonal loss in multiple sclerosis. Revue Neurologique 30, 1203-1208
148Yiangou, Y. et al. (2006) COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurology 6, 12
149Fujiwara, M. and Egashira, N. (2004) New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. Journal of Pharmacological Sciences 96, 362-366
150Ehrhart, J. et al. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Journal of Neuroinflammation 2, 29
151Sanchez, A.J. et al. (2006) R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochemical Pharmacology 72, 1697-1706
152Palazuelos, J. et al. (2008) The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. Journal of Biological Chemistry 283, 13320-13329
153Arevalo-Martin, A. et al. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. Journal of Neuroscience 23, 2511-2516
154Croxford, J.L. and Miller, S.D. (2003) Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R + WIN55,212. Journal of Clinical Investigation 111, 1231-1240
155Docagne, F. et al. (2007) Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Molecular and Cellular Neurosciences 34, 551-561
156Kuncl, R.W. et al. (1992) Motor neuron disease. In Diseases of the Nervous System (2nd edn) (Asbury, A.K., McKhann, G.M. and McDonald, W.I., eds), pp. 1179-1208, W. B. Saunders
157Babu, G.N. et al. (2008) Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochemical Research 33, 1145-1149
158Weydt, P. et al. (2005) Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 6, 182-184
159Bisland, L.G. et al. (2006) Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB Journal 20, 1003-1005
160Shoemaker, J.L. et al. (2007) The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Journal of Neurochemistry 101, 87-98
161Spencer, D.C. and Price, R.W. (1992) Human immunodeficiency virus and the central nervous system. Annual Review of Microbiology 46, 655-693
162Benito, C. et al. (2005) A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. Journal of Neuroscience 25, 2530-2536
163Williams, K. et al. (2001a) Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 36, 156-164
164Williams, K.C. et al. (2001b) Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. Journal of Experimental Medicine 193, 905-915
165Ghosh, S. et al. (2006) Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Molecular Immunology 43, 2169-2179
166Rubio-Araiz, A. et al. (2008) The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. Molecular and Cellular Neurosciences 38, 374-380
167Waksman, Y. et al. (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. Journal of Pharmacology and Experimental Therapeutics 288, 1357-1366
168Zhang, J. et al. (2003) Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. European Journal of Neuroscience 17, 2750-2754
169Benito, C. et al. (2007) Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. Journal of Neuroscience 27, 2396-2402
170Maresz, K. et al. (2005) Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. Journal of Neurochemistry 95, 437-445
171Ashton, J.C. et al. (2007) Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Letters 412, 114-117
172Benito, C. et al. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in alzheimer's disease brains. Journal of Neuroscience 23, 11136-11141
173Carrier, E.J. et al. (2005) Endocannabinoids in neuroimmunology and stress. Current Drug Targets – CNS & Neurological Disorders 4, 657-665
174Marciano-Cabral, F. and Cabral, G.A. (2003) Acanthamoeba spp. as agents of disease in humans. Clinical Microbiology Reviews 16, 273-307
175Cabral, G.A. (2005) Lipids as bioeffectors in the immune system. Life Sciences 77, 1699-1710
176Bouaboula, M. et al. (1993) Cannabinoid-receptor expression in human leukocytes. European Journal of Biochemistry 214, 173-180
177Lee, S.F. et al. (2001a) Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. Advances in Experimental Medicine and Biology 493, 223-228
178Lee, S.F. et al. (2001b) Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. European Journal of Pharmacology 423, 235-241
179Sinha, D. et al. (1998) Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. Journal of Neuroimmunology 82, 13-21
180Lynn, A.B. and Herkenham, M. (1994) Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. Journal of Pharmacology and Experimental Therapeutics 268, 1612-1623
181Kaminski, N.E. et al. (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Molecular Pharmacology 42, 736-742
Klein, T.W. (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology 5, 400-411
Ashton, J.C. and Glass, M. (2007) The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Current Neuropharmacology 5, 73-80
Arevalo-Martin, A. et al. (2008) CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. British Journal of Pharmacology 153, 216-225

Related content

Powered by UNSILO

Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation

  • Guy A. Cabral (a1) and LaToya Griffin-Thomas (a1)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.